241 results about "Biopharmaceutical" patented technology

The invention provides a biopharmacy downstream process optimization method and system based on machine learning. The method comprises the following steps: acquiring process parameters, process parameters and key quality attributes from a historical production process; preprocessing the technological parameters, the process parameters and the key quality attributes, performing feature construction, and selecting feature data; training a plurality of pre-acquired machine learning models based on the feature data, identifying key process parameters, evaluating the trained machine learning models according to a preset dimension, and selecting at least one optimal machine learning model according to an evaluation result; and performing parameter combination based on the key process parameters and a preset constraint range, inputting the combined parameters into at least one optimal machine learning model, and selecting a key process parameter combination meeting a preset quality standard according to an output result. According to the method, the problem that the key quality attributes are difficult to accurately predict and optimize in the existing biopharmacy downstream process is solved.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention relates to the field of biological medicine preparation, and particularly provides liraglutide precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from the N terminal to the C terminal, n is a positive integer from 4 to 6, the fusion peptide is SEQ ID NO.1, the target polypeptide is liraglutide precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.2, the isoelectric point of the recombinant fusion protein is 4.6-4.7, and the average hydrophilic value is-0.780--0.765. The proportion of the target polypeptide in the recombinant fusion protein is high, use of solvents under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

The invention relates to the field of computational biology and bioinformatics, in particular to an RNA (Ribonucleic Acid) sequence screening and promoter function predicting and screening method based on machine learning, which comprises the following steps of: firstly, adopting a novel sequence algorithm based on a sliding window and a position weight matrix, and combining technologies such as k-mer frequency analysis and conservative motif recognition; candidate RNA sequences are efficiently identified from genomic sequences. Then, an integrated prediction model fusing deep learning and traditional machine learning is established, and multi-dimensional information such as sequence features, structural features, functional features and evolution features is extracted; and carrying out batch prediction on the candidate RNA sequences, outputting a function intensity score and providing credibility evaluation. And finally, screening an RNA sequence with an optimal prediction result based on a multi-objective optimization strategy, and designing an experimental verification scheme. According to the method, the prediction accuracy and the screening efficiency are improved, the experiment cost can be remarkably reduced, and an efficient promoter screening tool is provided for the fields of synthetic biology, gene therapy, biological pharmacy and the like.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention relates to the field of biological medicine preparation, and particularly provides canagliflozin precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is a fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from an N terminal to a C terminal, n is a positive integer of 4-6, the fusion peptide is SEQ ID NO.1 or SEQ ID NO.2, the target polypeptide is a canagliptin precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.3, the isoelectric point of the recombinant fusion protein is 5.5-6.5, and the average hydrophilic value is-0.85--0.96. The invention creatively provides a method for preparing the canagliflozin precursor peptide by using a gene recombination technology, the proportion of the target polypeptide in the recombinant fusion protein is high, the use of a solvent under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

As a series of viscosity-reducing and stabilizing formulations for high-concentration protein formulations, they are finely tuned to significantly reduce the viscosity of high-concentration biopharmaceuticals and increase their stability. Viscosity-reducing and stabilizing formulations can be used for high-concentration biopharmaceutical products and have significant potential to improve stability during manufacturing and storage, thereby increasing the feasibility of high-concentration biopharmaceutical products.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

Provided are poly(ethylene glycol)-polyoxazoline (PEOZ) copolymers. In some cases, the PEOZ polymer has a repeat unit of structure –CH2N(C(O)R)CH2CH2OCH2CH2–. The PEOZ copolymers can be used in a variety of applications, e.g., to increase the solubility of various compounds, such as drugs, dyes and biopharmaceuticals. Also provided are methods of making the PEOZ copolymers, which in some cases can generate monodisperse compositions of PEOZ copolymers.

The present application relates to the technical field of biopharmaceuticals, and in particular, polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof based on artificial intelligence design and applications thereof are provided, wherein the amino acid sequence of the polypeptides is shown as SEQ ID NO:1.The polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof can simultaneously bind to PD-1 and CTLA-4, can effectively block the binding between PD-1 and CTLA-4 and their ligands respectively, release the inhibition of immune checkpoint proteins PD-1 and CTLA-4 on immune cells, and significantly enhance the anti-tumor immune response of the body. The polypeptides or derivatives thereof, pharmaceutically acceptable salts thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases related to PD-1 and / or CTLA-4.

Disclosed is a method implemented for outputting model(s) for developing or operating a process for a CGT. The method includes receiving, storing, and accessing data items; determining attributes of the data items; selecting one or more machine learning models based on the attributes; accessing one or more mechanistic models; integrating the one or more machine learning models with the one or more mechanistic models to obtain one or more integrated models; selecting one or more predictive models from the one or more machine learning models, the one or more mechanistic models, and the one or more integrated models; applying the one or more predictive models to the data items; adjusting one or more values of one or more parameters of the one or more predictive models to reduce uncertainty in model prediction; and outputting the one or more predictive models with the one or more adjusted values.

The invention discloses a biopharmaceutical high-pressure sterilization device, and belongs to the field of sterilization devices.The biopharmaceutical high-pressure sterilization device comprises a sterilization tank, the top of the sterilization tank is sleeved with a sealing cover, a water adding valve is arranged at the bottom of the outer surface of the sterilization tank, a water inlet funnel is arranged at the top of the water adding valve, and a third servo motor is fixedly connected to the bottom of the sterilization tank; the output end of the third servo motor is fixedly connected with a threaded rod, and the middle of the bottom in the sterilization tank is fixedly connected with a fixed shaft. A plurality of groups of material containing screen frames can synchronously rotate and rotate for a period of time, and a first servo motor rotates reversely to drive the material containing screen frames to rotate reversely, so that the material containing screen frames irregularly rotate forwards and backwards back and forth in the sterilization tank, medicines in the material containing screen frames irregularly move, and the positions of the medicines are continuously changed; therefore, medicine sterilization is more thorough, the situation that medicine cannot be thoroughly sterilized due to long-time standing is avoided, medicine components are prevented from being damaged by residual bacteria, and economic losses are reduced.

The invention relates to the technical field of biological medicine manufacturing, in particular to an environment-friendly and efficient Difelikefalin preparation method. According to the method, a solid-phase peptide synthesis technology is adopted, and the core is that a green mixed solvent system composed of 2-methyltetrahydrofuran and cyclopentyl methyl ether is used for comprehensively replacing traditional toxic solvents such as DMF and DCM. The method comprises the steps of resin swelling, Fmoc deprotection, amino acid coupling, peptide chain cutting, purification and freeze drying, a piperidine / 2-MeTHF solution is adopted in the deprotection, an optimized HATU / DIPEA activation system is adopted in the coupling reaction, a TFA / 2-MeTHF / water mixed solution is adopted in the cutting, and an ethanol-water chromatographic system is adopted in the purification. According to the invention, closed-loop circulation of the solvent is also realized, and 2-MeTHF and CPME are purified through rotary evaporation and reused in the synthesis process. According to the method, high purity and high yield of the product are guaranteed, production toxicity and environmental hazards are remarkably reduced, and the method has excellent industrial application prospects.

The sampling device comprises a sampling tank, a sealing cover and a protection piece, the sampling tank is arranged on the inner side of the protection piece, the sealing cover is arranged at the upper end of the sampling tank, the rear side of the upper end of the sealing cover is communicated with a guide pipe, the lower end of the rear side of the sampling tank is communicated with a conveying pipe, and the conveying pipe is communicated with the guide pipe. The protection piece comprises a supporting seat, a supporting frame, a supporting column and a connecting plate. The device has the beneficial effects that the sampling tank is placed above the supporting seat, the arc-shaped protection strip is attached to the back surface of the sampling tank, the supporting column is placed in the positioning cavity, and the mounting pin is inserted into the positioning cavity and extends into the through hole, so that the supporting column and the supporting frame are fixed; a supporting block and a rubber pad below the connecting plate are attached to a sealing cover above the sampling tank, so that the stability of the sampling tank during use is further improved, a user can directly take the sampling tank through a handle and the connecting plate without directly contacting the sampling tank, and the stability of the sampling tank is not influenced during movement.

This invention belongs to the field of cryogenic concentration technology, specifically relating to a cryogenic concentration method. It involves freezing a dilute solution into a solid or solid-liquid mixture, using gas as an energy medium, and leveraging the solid structure of the frozen material's surface and interior. Heat is transferred to the frozen material by applying negative or positive pressure. Through dissolution and separation, solutions are collected in stages to obtain solutions of different concentrations. Solutions meeting the target concentration are transferred to the next stage; solutions not meeting the target concentration are reused to further increase the concentration. This method improves the efficiency of cryogenic concentration and separation purification, is simple to operate, and is suitable for applications in food, cosmetics, biopharmaceuticals, petrochemicals, metal processing, and environmental protection.

The invention relates to the technical field related to biopharmacy, in particular to a biopharmacy multiple inactivation device which comprises a pretreatment module and a multiple inactivation module. The multi-inactivation module comprises a supporting piece located at the lower end of the pretreatment module, and a pulsed electric field inactivation unit, a thermal inactivation unit and an ozone oxidation inactivation unit which are arranged on the supporting piece and are distributed in a circumferential array; and a flow path switching mechanism. The pulse electric field inactivation unit, the thermal inactivation unit and the ozone oxidation inactivation unit are adopted, corresponding inactivation treatment is carried out according to different classifications of liquid medicine, the functions are diversified, and the inactivation mode is not limited to a single inactivation mode; the flow path of the liquid medicine can be switched through the flow path switching mechanism, so that the pretreated liquid medicine is hermetically connected with any one of the pulsed electric field inactivation unit, the thermal inactivation unit and the ozone oxidation inactivation unit through the supporting piece, and corresponding liquid medicine inactivation treatment is carried out by using one inactivation unit in the multiple inactivation module as required.

The utility model relates to the technical field of reaction kettles, and discloses a biopharmaceutical reaction kettle which comprises a reaction kettle body, lug seats are fixed on the outer side of the reaction kettle body, a blanking pipe is mounted at the bottom of the reaction kettle body, and supporting legs are fixed at the bottom of the reaction kettle body. Through the arrangement of the auxiliary cleaning mechanism, one end of the rotating frame pokes the moving rod to move back and forth, the anti-falling sliding plate drives the cast iron frame and the rubber column to move back and forth, the rubber column impacts the outer side of the discharging pipe back and forth, adhesion materials can be stripped in an auxiliary mode, and the situation that the purity of the next batch is affected due to residue degradation is reduced; by arranging the stabilizing mechanism, fixing between the mounting sleeve and the corresponding supporting leg is conveniently completed, at the moment, the corresponding faces of the outer shell and the metal support are attached, fixing between the outer shell and the metal support can be completed through bolts, the outer shell is easy to position and easy and convenient to assemble in the assembling process, and the assembling stability of the outer shell is improved.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to preparation and application of collagen peptide with whitening activity. The preparation method of the collagen peptide with the whitening activity comprises the following steps: step A, inoculating bacillus subtilis into a culture medium containing a moringa oleifera leaf extracting solution, fermenting for 6-12 hours, inoculating aspergillus niger, continuously fermenting for 36-48 hours, sterilizing, centrifuging, and taking supernate to obtain moringa oleifera leaf fermentation liquor; and step B, scaling the fish skin, cleaning, drying and crushing, adding the moringa oleifera leaf fermentation liquor, reacting for 6-10 hours at the pH value of 6.0-7.0 and the temperature of 35-45 DEG C, and performing ultrafiltration, filtrate concentration and freeze-drying to obtain the collagen peptide. The preparation process has the advantages of low cost, greenness and high efficiency, and the prepared collagen peptide shows the activity of inhibiting tyrosinase and can be applied to preparation of skin care products or medicines with a whitening function.

The application discloses an antibody glycosylation modification regulation method, device and application, relates to the technical field of biopharmaceuticals and protein engineering, and realizes directional regulation of modification types, modification sites and modification proportions of N-glycan and O-glycan of the antibody through three core processes of constructing a glycosyltransferase engineering strain, optimizing a fermentation culture system and precisely regulating modification reaction conditions; solves the technical problems of low modification efficiency, poor specificity and insufficient product uniformity in the existing modification method, can improve the target glycan modification proportion to more than 90%, the modification product purity is greater than or equal to 98%, is suitable for glycosylation modification optimization of therapeutic monoclonal antibodies, bispecific antibodies and antibody drug conjugates, significantly improves the biological activity and pharmacokinetic performance of the antibody, wherein the ADCC activity is improved by 3-5 times, and the CDC activity is improved by 2-4 times, and has the advantages of strong controllability, good adaptability to large-scale production and high cost-effectiveness.

The invention relates to the technical field of biological medicine preparations, and discloses a calcium, vitamin D and vitamin K. A content composition of the soft capsule comprises a microgel skeleton composed of amphiphilic polypeptide calcium ions and vitamin oil drops, the hydrophobic end of amphiphilic polypeptide adsorbs the oil drops, and the hydrophobic end of the amphiphilic polypeptide adsorbs the vitamin oil drops. A hydrophilic end of the composition is bridged by calcium ions to form a network, the composition also comprises a histidine-enriched polypeptide which can form a protective shielding layer on the surface of a skeleton under acidic pH, the calcium ions are converted from a chemical destroyer to a structural stabilizer, and a static synergistic system is constructed, so that the contact degradation of calcium and vitamins is eliminated, and the stability of the composition is improved. The performance contradiction between the high calcium content and the vitamin stability is avoided, and the endophytic environmental adaptability of the composition is improved.

The invention discloses a method for preparing a biomacromolecular drug delivery carrier based on a simple and efficient interface cross-linking system. An amphiphilic polymer monomer containing an epoxy group is prepared through RAFT polymerization so that the amphiphilic polymer monomer can exist on an oil-water interface, meanwhile, a three-arm cross-linking agent which has environmental sensitivity and is terminated by an amino group is prepared, and the amino group on the cross-linking agent and the epoxy group on the amphiphilic monomer are subjected to a cross-linking reaction on the oil-water interface; a drug delivery vehicle is formed. The carrier can entrap biomacromolecules and accurately target tumors through a high-permeability long-retention effect, and glutathione rich in a tumor microenvironment can break disulfide bonds in the carrier and release drugs entrapped in the carrier, so that the aim of treating the tumors is fulfilled. Therefore, the invention provides a drug delivery carrier which is simple, convenient, efficient in entrapment of biomacromolecules and high in stability, and the prepared carrier can be efficiently taken by tumor cells so as to regulate and control apoptosis of the tumor cells and is high in safety.

The present invention relates to the fields of biopharmaceuticals and biochemical engineering, and particularly relates to a method for preparing chiral β-trifluoromethyl alcohol compounds using non-heme iron enzyme BsQueD or its mutants. Using non-heme iron enzyme BsQueD or its mutants as catalysts, trifluoromethyl ketone as a substrate, and phenylsilane as a hydrogen source, chiral β-trifluoromethyl alcohol is obtained after the reaction. The amino acid sequence of the non-heme iron enzyme BsQueD is shown in SEQ ID NO.1. It has a high conversion rate (70%) for the substrate trifluoromethyl ketone, high optical activity of the product β-trifluoromethyl alcohol (e.e. value greater than 90%), and high yield, greatly reducing the production cost.

The invention relates to the technical field of biological medicines, and particularly discloses a chronic wound healing promoting traditional Chinese medicine compound loaded wound and ulcer paste, which comprises a hydrogel matrix and a traditional Chinese medicine compound, and the traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 5-15 parts of rheum officinale, 4-8 parts of bletilla striata, 15-25 parts of astragalus membranaceus, 5-15 parts of salvia miltiorrhiza, 1-5 parts of cinnamon and 0.5-1.5 parts of borneol. The wound and ulcer paste loaded with the traditional Chinese medicine compound for promoting chronic wound healing can continuously and stably act on a target organ, the wound is isolated from the outside to prevent infection, meanwhile, the drug effect can be better brought into play, and therefore the treatment effect of chronic wound healing is improved.

This invention provides a high-recovery heme iron extraction method and apparatus using enzymatic hydrolysis-multi-stage centrifugal coupling, relating to the fields of biopharmaceuticals and fluid dynamics processing technology. The method first constructs a polyanionic electrolyte shielding system, utilizing electrostatic potential energy to induce conformational instability of globin and pre-exposure of hydrophobic cavities, reducing binding energy at the molecular level and solving the problem of heme's encapsulation resistance in high-concentration systems. Then, high-shear coupled enzymatic hydrolysis is performed within a micron-sized liquid film generated by a hypergravity field, utilizing the instantaneous synergy of mechanical shear stress and enzymatic degradation to achieve directional exfoliation of heme, eliminating secondary re-adhesion effects. Finally, directional phase transition regulation is performed based on density gradient drive, and a high-frequency pulsed pressure field is introduced for in-situ exchange washing, distinguishing and retaining impurities and crystal cores, outputting a high-purity, flavor-neutral heme iron product. This invention effectively improves the controllability of the extraction process and the stability of industrial continuous production.

The application discloses a method for preparing vitamin D3 by visible light catalysis and belongs to the field of biological medicine product manufacturing. The method uses 7-dehydrocholesterol (7-DHC) as raw material, selects tetrabromofluorescein as a catalyst under visible light with a wavelength of 400-780 nm, and 7-DHC is selectively opened to form previtamin D3 (P3) and then isomerized to vitamin D3 by heat. The method can obtain a high-yield (84%) vitamin D3 product by irradiation for only 90 seconds. The method for preparing vitamin D3 by visible light catalysis overcomes the technical bottleneck of the previous ultraviolet light catalysis, avoids the damage to the human body and the environment caused by ultraviolet light irradiation, is more green and environmentally friendly, has high selectivity, short reaction time and high efficiency, and has a wide industrialization prospect.

The utility model discloses a novel biological medicine detection device, which relates to the technical field of biological medicine detection equipment, and comprises an equipment main body, a bearing mechanism for moving and placing the equipment main body is arranged in the lower end of the equipment main body, and the bearing mechanism further comprises an adsorption assembly for enhancing the fixing strength of the equipment. The cantilever is driven to rotate through the two transverse shafts to drive the second connecting block and the suction cup to continuously approach the table top, the suction cup is firstly continuously extruded, then the second connecting block drives the mounting sleeve and the T-shaped sliding block to continuously move downwards on the inner wall of the connecting pipe, and after the T-shaped sliding block moves to the bottom of the connecting pipe, the suction cup is driven to rotate. Each set of limiting grooves is in sealed sliding connection with the first sliding rail and the second sliding rail, at the moment, the suction cups are squeezed to the limit, air in the suction cups is squeezed to be exhausted, negative pressure generated by the multiple sets of suction cups is used for enhancing the connection strength of the equipment body and the working table, and when the equipment body needs to be moved, only the operation needs to be conducted conversely.

The present disclosure relates to methods, devices and systems for exposing microorganisms or compositions comprising functional proteins to an oscillating electric field substantially free of a magnetic component in order to improve stress responses, survival and metabolite or protein production. In embodiments, a controller drives one or more insulated emitters with a true AC signal or pulsed DC signal, in stepped, swept or shuffled patterns of an electric field oscillating at one or more frequencies in the range 210 Hz to 99 kHz. Exposure to the field provides surmounting energy that enhances protein breathing, catalysis, and fundamental functions of multiprotein complexes including transcription factors and ribosomes, thereby improving stress resistance of microorganisms, their viability during fermentation, drying, storage, transport, and / or increasing production of functional or therapeutic proteins, metabolites or microbial lysates. The technology is applicable to manufacture of probiotics, therapeutics, metabolites, food, alcohol, feed and bioenergy, cosmetics, nutraceuticals and biopharmaceuticals..

The invention discloses a biological medicine active component screening method and system based on artificial intelligence, and relates to the technical field of biological medicine manufacturing. The method comprises the following steps: acquiring component characteristic parameters and performance parameters of a biological medicine formula to be optimized; constructing and acquiring a performance prediction model, and acquiring a performance prediction confidence coefficient based on the component characteristic parameters and the performance parameters; on the basis of the component features, obtaining an optimization feasible region in combination with the performance prediction confidence; performing iterative optimization in the optimization feasible region by adopting a particle swarm algorithm to obtain an optimized biological medicine formula, and obtaining optimized performance parameters of the optimized biological medicine formula based on the performance prediction model; and according to the optimized biological medicine formula and the optimized performance parameters, generating a biological medicine active component screening result. The screening efficiency and precision of the active ingredients of the biological medicine are effectively improved.

The invention relates to the field of biological medicine manufacturing, in particular to a trollius chinensis bunge anti-inflammatory active component extraction and purification process which comprises the following steps: step (1), weighing trollius chinensis bunge powder and ferroferric oxide powder according to a mass ratio of 100: (1-10) for later use; (2) carrying out ball milling on the trollflower powder and the ferroferric oxide powder to obtain slurry; (3) carrying out microwave extraction on the obtained slurry; (4) carrying out solid-liquid separation to obtain an extracting solution containing flavone; and (5) adsorbing the extracting solution obtained in the step (4) through a macroporous adsorption resin column, then eluting with an ethanol water solution, collecting the eluent, concentrating and drying to obtain a high-purity trollflower flavone product. On the basis of a microwave extraction method, ferroferric oxide powder is introduced, efficient recovery of trollflower flavone is achieved, the product yield reaches 17.5%, and the purity exceeds 57%.

The invention discloses a method for rapidly preparing host cell DNA (deoxyribonucleic acid), which comprises the following steps: S1, pretreatment: adding a sodium salt buffer solution and a precooled ethanol solution into affinity chromatography loading flow-through liquid, magnetically stirring, and standing and incubating at low temperature; s2, capturing by a microporous filter: filtering the pretreated liquid through a micron-aperture filter, and intercepting host cell DNA precipitate; s3, emptying treatment: emptying residual liquid of the micron-aperture filter, and removing residual ethanol through nitrogen purging; s4, circulating dissolution: enabling a dissolution buffer solution to circularly pass through a micron-aperture filter at a set flow rate, and dissolving the intercepted host cell DNA; s5, collection of a target product: collecting a dissolution buffer solution containing the host cell DNA to obtain the target product. The method is controllable in cost, the purity and concentration of the product meet the standard adding requirements of an impurity removal verification experiment in the field of biopharmacy, the experiment reliability and economical efficiency are remarkably improved, and a key technical support is provided for quality control of biological products.